Differential \u3cem\u3eFmo3\u3c/em\u3e gene expression in various liver injury models involving hepatic oxidative stress in mice by Rudraiah, Swetha et al.
University of Rhode Island
DigitalCommons@URI
Biomedical and Pharmaceutical Sciences Faculty
Publications Biomedical and Pharmaceutical Sciences
2014
Differential Fmo3 gene expression in various liver
injury models involving hepatic oxidative stress in
mice
Swetha Rudraiah
Jamie E. Moscovitz
See next page for additional authors
Creative Commons License
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0
License.
Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs
This is a pre-publication author manuscript of the final, published article.
This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted
for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Rudraiah, S., Moscovitz, J. E., Donepudi, A. C., Campion, S. N., Slitt, A. L., Aleksunes, L. M., & Manautou, J. E. (2014). Differential
Fmo3 gene expression in various liver injury models involving hepatic oxidative stress in mice. Toxicology, 325, 85-95. doi: 10.1016/
j.tox.2014.08.013
Available at: https://doi.org/10.1016/j.tox.2014.08.013
Authors
Swetha Rudraiah, Jamie E. Moscovitz, Ajay C. Donepudi, Sarah N. Campion, Angela L. Slitt, Lauren M.
Aleksunes, and José E. Manautou
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/120
Differential Fmo3 Gene Expression in Various Liver Injury 
Models Involving Hepatic Oxidative Stress in Mice
Swetha Rudraiaha, Jamie E. Moscovitzb, Ajay C. Donepudid, Sarah N. Campionc, Angela L. 
Slittd, Lauren M. Aleksunesb, and José E. Manautoua
aDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA
bDepartment of Pharmacology and Toxicology, Rutgers UniversityErnest Mario School of 
Pharmacy, Piscataway NJ, USA
cDrug Safety Research and Development, Pfizer, Inc., Groton, USA
dDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, 
RI, USA
Abstract
Flavin-containing monooxygenase-3 (FMO3) catalyzes metabolic reactions similar to cytochrome 
P450 monooxygenase however, most metabolites of FMO3 are considered non-toxic. Recent 
findings in our laboratory demonstrated Fmo3gene induction following toxic acetaminophen 
(APAP) treatment in mice.The goal of this study was to evaluate Fmo3gene expression in 
diverseother mouse models of hepatic oxidative stress and injury. Fmo3 gene regulation by Nrf2 
was also investigated using Nrf2 knockout (Nrf2 KO) mice. In our studies, male C57BL/6J mice 
were treated with toxic dosesof hepatotoxicants or underwent bile duct ligation (BDL, 10d). 
Hepatotoxicants included APAP (400 mg/kg, 24 to 72h), alpha-naphthylisothiocyanate (ANIT; 50 
mg/kg, 2 to 48h), carbontetrachloride (CCl4;10 or 30 μL/kg, 24 and 48h) and allyl alcohol (AlOH; 
30 or 60 mg/kg, 6 and 24h). Because oxidative stress activates nuclear factor (erythroid-derived 
2)-like 2 (Nrf2), additional studies investigated Fmo3 gene regulation by Nrf2 using Nrf2 
knockout (Nrf2 KO) mice. At appropriate time-points, blood and liver samples were collected for 
assessment of plasma alanine aminotransferase (ALT) activity, plasma and hepatic bile acid 
levels, as well as liver Fmo3 mRNA and protein expression. Fmo3 mRNA expression increased 
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significantly by 43-fold at 12h after ANIT treatment,and this increase translates to a 4-fold change 
in protein levels. BDL also increased Fmo3 mRNA expression by 1899-fold, but with no change 
in protein levels. Treatment of mice with CCl4decreased liver Fmo3gene expression, whileno 
change in expression was detected with AlOH treatment. Nrf2 KO mice are more susceptible to 
APAP (400 mg/kg, 72h) treatment compared to their wild-type (WT) counterparts, which is 
evidenced by greater plasma ALT activity. Fmo3 mRNA and protein expression increased in Nrf2 
KO mice after APAP treatment. Collectively, not all hepatotoxicantsthat produce oxidative stress 
alter Fmo3gene expression. Along with APAP, toxic ANIT treatment in mice markedly 
increasedFmo3 gene expression. While BDL increased Fmo3 mRNA expression, protein level did 
not change. The discrepancy with Fmo3 induction in cholestatic models, ANIT and BDL, is not 
entirely clear. Results from Nrf2 KO mice with APAP suggest that the transcriptional regulation 
of Fmo3 during liver injury may not involve Nrf2.
Keywords
Flavin-containing monoxygenase-3; Hepatotoxicants; Acetaminophen; Alpha-
naphthylisothiocyanate; Bile duct ligation; Carbon tetrachloride; Allyl alcohol; Oxidative stress; 
Nrf2
1. Introduction
Drug-induced liver injury (DILI) is a significant challenge for both drug development and 
clinical care. It accounts for more than 50% of all acute liver failure cases in the U.S. 
(Larson et al., 2005; W. M. Lee, 2010). Many chemicals, such as acetaminophen (APAP), 
carbontetrachloride (CCl4) and allyl alcohol (AlOH) have been used to model hepatotoxicity 
relevant to human exposure. Alpha-naphthylisothiocyanate (ANIT) and bile duct ligation 
(BDL) on the other hand are used to model cholestasis, a pathological condition caused by 
impairment of hepatic bile flow. While ANIT produces intrahepatic cholestasis, BDL 
produces extrahepatic cholestasis. With APAP and CCl4, the parent compound is 
metabolized by cytochrome P450 (CYP) to generate reactive metabolites, N-acetyl-p-
benzoquinone imine (NAPQI) and tricholoromethyl radical (·CCl3), respectively.AlOHin 
turn is metabolized in the liver by alcohol dehydrogenase to its reactive metabolite, acrolein. 
The glutathione adductof acrolein is converted by CYPs to glycidaldehyde. Toxicity 
resulting from these reactive metabolites is multifactorial and includes lipid peroxidation, 
generation of oxidative stress, altered cellular redox status and protein adduct 
formation(Burcham & Fontaine, 2001; Cohen et al., 1997; Jaeschke et al., 2012; Ohno et al., 
1985; Tom et al., 1984). During cholestasis resulting from either BDL or ANIT treatment, 
increase in bile acid concentration stimulates production of reactive oxygen species 
eventually leading to hepatocellular necrosis and apoptosis (Sokol et al., 1995; Trauner et 
al., 1998).
The role of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) role as a master defense against 
hepatotoxicity produced by various chemicals has been investigated in several studies. Nrf2 
belongs to the cap ‘n’ collar family of transcription factors that promotes transcription of a 
battery of cytoprotective genes(Aleksunes & Manautou, 2007; Kensler et al., 2007). Under 
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basal conditions, Nrf2 is largely bound to the cytoskeletal anchoring protein Kelch-like 
ECH-associated protein 1 (Keap1) also known as cytosolic Nrf2 inhibitor in the 
cytoplasm.In response to oxidative stress, Nrf2 is released from Keap1 andtranslocatesto the 
nucleus. In the nucleus, Nrf2 binds to the GTGACA***GC core sequence of the antioxidant 
response element (ARE) (Rushmore et al., 1991) and promotes ARE-mediated antioxidant 
gene expression.
A low toxic APAP dose causes nuclear accumulation of Nrf2 in mouse liver, which is 
accompanied by increased expression of Nrf2 dependent cytoprotectivegenes such as heme 
oxygenase-1 (Hmox1), NAD(P)H:quinone oxidoreductase-1 (Nqo1) and glutamate cysteine 
ligase catalytic subunit (Gclc) (Aleksunes et al., 2005; Aleksunes et al., 2006; Bauer et al., 
2000; Chiu et al., 2002; Goldring et al., 2004). Similar results have been reported with 
ANIT, BDL, CCl4 and AlOH, other models of hepatic oxidative stress used in the present 
study(Aleksunes et al., 2005; Aleksunes et al., 2006; Liu et al., 2013; Randle et al., 2008; 
Tanaka et al., 2009). On the other hand, Nrf2 KO mice are more susceptible to APAP-
induced liver injury compared to their wild-type counterparts (Chan et al., 2001; Enomoto et 
al., 2001). Likewise, Nrf2 KO mice arealso more susceptible to CCl4- andAlOH-induced 
hepatoxicity compared towild-type mice (Liu et al., 2013). However, Nrf2 KO mice do not 
exhibit any difference in susceptibility to either BDL or ANIT treatment(Tanaka et al., 2009; 
Weerachayaphorn et al., 2012). This response is attributed to the adaptive compensatory 
changesinvolving nuclear transcription factors, including Fxr, Shp, Pxr andHnf1α, efflux 
bile acid transporters, altered GSH levels and bile flow rates in Nrf2 KO mice (Tanaka et al., 
2009; Weerachayaphorn et al., 2012). Collectively, the models of hepatic injury selected for 
the current study not only result in hepatic oxidative stress but also activate the Nrf2-Keap1 
regulatory pathway.
Despite Fmo3 being considered non-inducible, studies with aryl hydrocarbon receptor 
(AhR) agonists in mice revealed liver Fmo3 gene induction (Celius et al., 2008; Celius et al., 
2010). A recent gene array analysis performed in our laboratory also demonstrated Fmo3 
gene induction in the APAP autoprotection mouse model (mice receiving a low hepatotoxic 
APAP dose that become resistant to a subsequent higher APAP dose)(O'Connor et al., 
2014).Unlike with AhR agonists that result in marginal increases in Fmo3 protein expression 
in mouse liver, we showed significant increases in Fmo3 protein levels by 15-fold in APAP 
autoprotectedmice(Rudraiah et al., 2014). Fmo3 induction by other hepatotoxicants that 
produce oxidative stress is not currently known.
In human liver, transcription factors regulating constitutive FMO3expression as well as 
those involved in developmental expression pattern have been extensively studied (Klick & 
Hines, 2007; Klick et al., 2008; Shimizu et al., 2008). Because the mammalian FMOs were 
considered non-inducible by xenobiotics (Cashman & Zhang, 2002; Krueger & Williams, 
2005), the transcriptional regulation of FMO involving stress-activated transcription 
factorsor receptors that bind ligands andinteract with DNAwas not studied as other forms of 
regulation. Thus, little is known about the transcriptional regulation of Fmo3 in response to 
toxicant exposure. Recently, Celius et al. (2010) showed that the Fmo3 mRNA up-regulation 
by 3-methylcholanthrene (3MC) and benzo(a)pyrene (BaP) but not TCDD in Hepa-1 cells is 
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mediated by p53 and its binding to a p53-response element in the promoter region of 
Fmo3(Celius et al., 2010).
Differentially expressed genes in the APAP autoprotection model were further analyzed 
usingCausal Reasoning Engine (CRE), a recently developed computational platform 
(O'Connor et al., 2014). CRE analysis provides hypotheses on the upstream molecular 
events that best explain gene expression profiles based on prior biological knowledge. CRE 
analysis of differentially expressed genes in APAP autoprotection study supportsan 
induction of the Nrf2 pathway (O'Connor et al., 2014). Additionally, the 5'-flanking region 
of the mouse Fmo3 contains multiple copies of the ARE (Celius et al., 2008). Therefore, the 
purpose of the present study was to investigate liver Fmo3gene expression under oxidative 
stress conditions involving activation of the Nrf2-Keap1 regulatory pathway. Mice were 
dosed with hepatotoxicants APAP(400 mg/kg, 24 to 48h), ANIT (50 mg/kg, 2 to 48h), 
CCl4(10 or 30 μL/kg, 24 and 48h) or AlOH (30 or 60 mg/kg, 6 and 24h)orunderwent sham 
surgery or bile duct ligation (10d). Doses selected for hepatotoxicants are based upon 
previous studies conducted in our laboratory resulting in oxidative stress and tissue injury. 
The inclusion of multiple time-points followinghepatotoxicantsexposure enabled 
comprehensive characterization of temporal changes in Fmo3 in relation to injury and 
recovery. Further, in order to investigate whether Nrf2 mediatesFmo3 gene expression, Nrf2 
KO mice were employed. APAP was used as a model toxicant in the Nrf2 KO mice study. 
From these experiments,it is concluded that not all hepatotoxicantsthat produce oxidative 
stress in mice induce liver Fmo3 gene expression. Toxic ANIT treatment, along with the 
previously demonstrated APAP treatment, markedly increases Fmo3 gene expression. While 
BDL increases Fmo3 mRNA expression, protein levels do not change.APAP treatment 
induces Fmo3 gene expression in Nrf2 KO mice liver suggesting that the transcriptional 
regulation of Fmo3 might not involve Nrf2.
2. Materials and Methods
2.1. Chemicals
Acetaminophen, alpha-naphthylisothiocyanate, carbon tetrachloride, allyl alcohol, propylene 
glycol and corn oil were purchased from Sigma-Aldrich (St Louis, MO). All other reagents 
were of reagent grade or better and commercially available.
2.2. Animals
Male C57BL/6J mice (9- to10-week old)were purchased from Jackson Laboratories (Bar 
Harbor, ME) for this study. Upon arrival, mice were acclimated for one week prior to 
experimentation. Mice were housed in a temperature-, light- and humidity-controlled 
environment. Mice were fed laboratory rodent diet (Harlan Teklad 2018, Madison, WI) ad 
libitum.
2.2.1 Experimental Design 1—The primary objective of experimental design 1 was to 
evaluate liver Fmo3 gene expression under oxidative stress conditions involving activation 
of the Nrf2-Keap1 regulatory pathway. All hepatotoxicant treatments were performed after 
an overnight fast, and mice were re-fed 8 h after treatment. Each treatment group consisted 
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of six mice. For APAP treatment, mice were treated with APAP (400 mg/kg, ip) in 50% 
propylene glycol or vehicle only (dosing volume: 5 mL/kg). Animals were sacrificed by 
decapitation at 24, 48 and 72 h after treatment and blood and livers were collected for 
analysis. For ANIT treatment, mice were administered ANIT (50 mg/kg, po) in corn oil or 
vehicle only (dosing volume: 10 mL/kg). At 2, 4, 8, 12, 24 and 48 h after treatment, mice 
were sacrificed by decapitation for collecting samples. For CCl4 treatment, groups of mice 
were injected CCl4 (10 or 30 μL/kg, ip) in corn oil or vehicle only (dosing volume: 6 
mL/kg) and 24 and 48 h after treatment, mice were sacrificed by decapitation to collect 
blood and livers for analysis. For AlOH treatment, mice were administered AlOH (30 or 60 
mg/kg, ip) in saline or vehicle only (dosing volume: 10 mL/kg). Animals were sacrificed by 
decapitation at 6 and 24 h after treatment for sample collection and analysis. BDL liver 
samples were obtained from a previously described cohort (Donepudi et al., 2012). Briefly, 
sham or BDL surgery was performed under phenobarbital-induced anesthesia (65 mg/kg, 
ip). The surgeries were performed at the University of Rhode Island, College of Pharmacy 
animal facility with IACUC approval. Serum and liver were collected 10 d after surgery for 
analysis.
2.2.2 Experimental Design 2—The goal of experimental design 2 was to investigate 
whether Nrf2 mediateschanges in liverFmo3 gene expression. APAP was used as a model 
toxicant for Nrf2 activation.Nrf2 KO mice with a C57BL/6J background werekindly 
provided by Dr. Angela Slitt from the University of Rhode Island.Following overnight 
fasting, male Nrf2KO mice (n=6) and their wild-type counterparts (C57BL/6J) (n=6) were 
treated with APAP (400 mg/kg, ip) in 50% PG or vehicle (dosing volume: 5 mL/kg). Plasma 
and livers were collected 72h after APAP treatment for analysis.
All animal studies were performed in accordance with National Institute of Health standards 
and the Guide for the Care and Use of Laboratory Animals. This work was approved by the 
University of Connecticut's Institutional Animal Care and Use Committee.
2.3 Alanine Aminotransferase (ALT) Assay
Plasma or serum ALT activity was determined as a biochemical indicator of hepatocellular 
injury. Infinity ALT Liquid Stable Reagent (Thermo Fisher Scientific Inc., Waltham, MA) 
was used to determine ALT activity. Briefly, 100 μL of reagent was added to 10 μL serum or 
plasma samples, and absorbance was measured spectrophotometrically at 340 nmusing a 
Bio-Tek Power Wave X Spectrophotometer. ALT activity (IU/L) was determined using the 
molar extinction coefficient of NADH (6.3 mM−1cm−1).
2.4 Total Bile acid Assay
Total bile acids were extracted from whole liver homogenates using a t-butanol extraction 
method. Briefly, livers were homogenized in extraction solution (1:1, water: tbutanol) and 
bile acids extracted overnight at room temperature in the dark. Blood levels of total bile acid 
and hepatic bile acid levels were measured using a spectrophotometric bile acid assay kit 
(Bioquant, San Diego, CA) according to manufacturer's protocol.
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2.5 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from mouse liver samples using TRIzol reagent (Life 
Technologies, Carlsbad, CA) according to the manufacturer's instructions. Total RNAwas 
then reverse-transcribed into cDNA using an M-MLV RT kit (Invitrogen, Carlsbad, CA). 
Fmo3 mRNA expression was quantified by the ΔΔCT method and normalized to two 
housekeeping genes, β-actin and ribosomal protein S18. Data presented were normalized to 
β-actin. Primer pairs were synthesized by Integrated DNA Technologies (Coralville, IA) and 
are as follow: Fmo3 forward: 5′-GGA AGA GTT GGT GAA GAC CG-3′, reverse: 5′-CCC 
ACA TGC TTT GAG AGG AG-3′. Amplification was performed using an Applied 
Biosystems 7500 Fast Real-Time PCR System. Amplification was carried out in a 20μL 
reaction volume containing 8 μL diluted cDNA, Fast SYBR Green PCR Master Mix 
(Applied Biosystems, Foster City, CA) and 1μM of each primer.
2.6 Preparation of Microsomal Fraction and Western Blot Analysis
Microsomes were isolated from livers as described previously (Cashman &Hanzlik, 1981; 
Rudraiah et al., 2014) and stored at −80°C until use. Protein concentration was determined 
by the method of Lowry using Bio-Rad protein assay reagents (Bio-Rad Laboratories, 
Hercules, CA). For western blot analysis, microsomal proteins (10 μg) were 
electrophoretically resolved using 10% polyacrylamide gels and transferred onto PVDF-Plus 
membrane (Micron Separations, Westboro, MA). Membranes were blocked with 5 % non-
fat powdered milk in tris buffered saline containing 0.05% tween-20(TBS-T) for 8 h. A 
rabbit anti-mouse Fmo3 primary antibody (GenScript USA Inc., NJ) (1:5000) was used to 
detect Fmo3 with β-actin as a loading control. Blots were then incubated with HRP 
conjugated secondary antibodies against rabbit IgG (1:2000) (Sigma-Aldrich, St Louis, 
MO). Protein-antibody complexes were detected using a chemiluminescent kit (Thermo 
Scientific, IL) with visualization using GeneMate blue autoradiography film (Bioexpress, 
Kaysville, UT). Precision plus protein dual color standards molecular weight marker (Bio-
radLaboratories, Hercules, CA) was used to identify Fmo3 protein on the blot and 
microsomal protein isolated from naïve female mouse liver was used as a positive control.
2.7 Enzyme Assay
Methimazole (MMI) metabolism was determined spectrophotometrically by measuring the 
rate of MMI S-oxygenation via the reaction of the oxidized product with nitro-5-
thiobenzoate (TNB) to generate 5,5’-dithiobis(2-nitrobenzoate) (DTNB). The incubation 
mixture consisted of 50 mM sodium phosphate buffer (pH 9.0), 0.5 mM NADP+, 0.5 mM 
glucose-6-phosphate, 1.5 IU/mL glucose-6-phosphate dehydrogenase, 0.06 mM DTNB, 0.04 
mMdithiothreitol and 100 to 150 μg/mL liver microsomes isolated from mice. Reactions 
were initiated by the addition of different amounts of MMI (substrate), with a concentration 
range from 1.25 to 800 μM. Incubations were done in duplicates. The disappearance of the 
yellow color was measured spectrophotometrically at 412 nm and specific activity 
(μM/min/mg) was determined using the molar extinction coefficient of NADPH (28.2 
mM−1cm−1).
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2.8 Statistical Analysis
The statistical significance between groups was determined using the Student's t-test, one-
way ANOVA with Dunnett's post-hoc test or two-way ANOVA followed by the 
Bonferroni'spost-hoc test. While Student's t-test was used to compare means of two different 
treatment groups, ANOVA was used to compare the means of more than two treatment 
groups that are normally distributed with a common variance. All statistical analysis was 
performed using GraphPad Prism version 4.00 for Macintosh (GraphPad Software, Inc., San 
Diego, CA). Data are presented as mean ± standard error (SE), with p<0.05 considered 
statistically significant.
3. Results
3.1 Plasma ALT Activity in the Mouse Liver Injury Models
The time-points selected for the single dose APAP (400 mg/kg)treatment studyin mice were 
based on the previous studies that demonstrated Fmo3 mRNA and protein peaks at 48 h and 
72 h, respectively(O'Connor et al., 2014; Rudraiah et al., 2014). The hepatotoxicity of a 
single dose APAP (400 mg/kg) at 24, 48 and 72 h as assessed by plasma ALT activity has 
been reported previously (Rudraiah et al., 2014). Briefly, APAP increased plasma ALT 
activity to 191±18 and 219±47IU/L at 24 and 48 h, respectively (mean plasma ALT activity 
in control mice was 25±5IU/L). Plasma ALT activity was not statistically different from 
vehicle controlsby 72 h, indicating recovery from APAP-induced liver injury.Plasma ALT 
activity in all mouse models of liver injury is shown in Figure 1. ANIT increased ALT 
activity at 12 h (182±9 IU/L), which continued to increase at 24 and 48 h (715±126 IU/L 
and 781±45 IU/L, respectively) compared to vehicle control group (9±1 IU/L). BDL for 10 
d results in an elevation of ALT activity to 185±10 IU/L. A high CCl4 dose (30 μL/kg) 
increased plasma ALT at 24 and 48 h to 6367±1135 and 397±111 IU/L, respectively. A low 
CCl4 dose (10 μL/kg) also increased plasma ALT activity at 24 and 48 h to 757±106 and 
416±68 IU/L, respectively. The greatest increase in plasma ALT with both doses of CCl4 is 
observed at 24 h. While AlOHtreatment (low dose, 30 mg/kg) did not result in significant 
increases in ALT levels at 6 h and 24 h (36±4 and 73±24 IU/L, respectively),a high 
AlOHdose (60 mg/kg) results in significantly higher ALT levels at both 6 h and 24 h 
(153±50 and 4440±2428 IU/L, respectively). The associated histopathological damage with 
all hepatotoxicants has been reported previously(Aleksunes et al., 2005; Aleksunes et al., 
2006; Campion et al., 2009; Donepudi et al., 2012; Rudraiah et al., 2014). With acute 
toxicity models, plasma ALT activity lesser than 1000 IU/L is usually associated with a 
minimal to mild hepatocellular damage (histological grade of 2 or less than 2), and an ALT 
activity higher than 1000 IU/L is associated with moderate, marked or severe hepatocellular 
damage (histological grade of 3, 4, or 5) (Aleksunes et al., 2008; Manautou et al., 1994). 
Alternatively, a 10 d BDL with an associated ALT activityof less than 200 IU/L, exhibit a 
chronic hepatocellular damage involving fibrosis (Donepudi et al., 2012).
3.2 Hepatic Bile Acid Concentrations in the Mouse Liver Injury Models
To determine the extent of cholestasis induced by different hepatotoxicants used in the 
current study, total hepatic bile acid levels were measured (Figure 2). As expected ANIT 
increased hepatic bile acid levels to 1.7±0.2 and 1.6±0.4 μmol/g at 24 and 48 h, respectively, 
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compared to 0 h vehicle control group (0.2±0.02 μmol/g). BDL also increased hepatic bile 
acid concentrations to 19.49±0.85 μmol/100 mg compared to sham operated group 
(10.61±1.65 μmol/g). No significant changes were observed in mice treated with APAP, 
CCl4 and AlOH.
3.3 Total bile Acid Concentrations in the Blood in the Mouse Liver Injury Models
Bile acid concentration in plasma is also a biomarker of cholestasis. In order to determine 
the extent of cholestasis,plasma bile acid levels were also quantified in all mouse models of 
liver injury (Figure 3). Plasma bile acid concentration increased in ANIT treated mice at 24 
and 48 h to 210±20 and 330±128 μmol/L, respectively, compared with vehicle treated mice 
(2±0.2 μmol/L). Bile duct ligation significantly increased serum bile acid levels to 1359±142 
μmol/L compared to sham operated mice (86±11 μmol/L). Significant increases in plasma 
bile acid concentrationsare seen in high dose CCl4 treated mice at both 24 and 48 h (112±15 
μmol/Land 29±2 μmol/L, respectively). Exposure to APAP and AlOH did not result in any 
significant change in plasma bile acid levels.
3.4 Hepatic Fmo3 mRNA Expression in the Mouse Liver Injury Models
Fmo3 mRNA levels were quantified by qRT-PCR and the results are presented in Figure 4. 
Fmo3 mRNA expression following a single dose APAP 400 mg/kg treatment has been 
previously reported (Rudraiah et al., 2014). Briefly, Fmo3 mRNA levelsincreased by 5±2.6-
and 23±5.6-fold, at 24 and 48 h after APAP, respectively, compared to the 0 h control group. 
ANIT increased Fmo3 mRNA levels as early as 2 h after treatment. This increase peaked 
and is statistically significant only at 12 h (43±10-fold increase), compared to 0 h vehicle 
control group. BDL also increased Fmo3 mRNA expression by 1899±625-fold, compared to 
sham operated mice. Both the low and high dose of CCl4decreased Fmo3 mRNA levels at 
both time-points examined, and this decrease is statistically significant only at 48 h (10 
μL/kg: 0.2±0.06-fold and 30 μL/kg: 0.2±0.08-fold). No change in liver Fmo3 mRNA levels 
was observed with AlOH treatment.
3.5 Fmo3 Protein Expression in the Mouse Liver Injury Models
Temporal expression of the Fmo3 protein following exposure to hepatotoxicants and BDL 
were quantified by western blotting. Representative blots and associated densitometric 
analyses are shown in Figure 5. Fmo3 protein increase following APAP treatment has been 
previously reported (Rudraiah et al., 2014). Although the expression of Fmo3 protein tended 
to increase by 1.1±0.3-to 1.6±0.2-fold between 24 and 72 h after APAP, the increase is 
statistically significant only at 72h. Consistent with Fmo3 mRNA changes evidenced with 
ANIT treatment, Fmo3 protein levels also tend to increase as early as 2 h. However, this 
increase is significant only at 12 h (3.5±0.9-fold) compared to 0 h vehicle treated group. 
Fmo3 protein levels decreased to 0.7±0.08- and 0.3±0.1-fold at 24 and 48h, respectively, 
after exposure to ANIT. Conversely, in spite of the dramatic increase in Fmo3 mRNA levels 
after BDL, Fmo3 protein levels did notchange. No significant changes in Fmo3 protein 
expression are observed with CCl4 orAlOH treatment.
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3.6 Plasma ALT Activity and Fmo3 mRNA Levels after APAP Treatment in Wild-Type and 
Nrf2 Knockout Mice
All models of hepatic injury used in the current study activate the Nrf2-Keap1 regulatory 
pathway. Furthermore, CRE analysis of differentially expressed genes in our APAP 
autoprotection study supportedan induction of the Nrf2 pathway (O'Connor et al., 2014). To 
investigate whether Nrf2 mediatesFmo3 gene expression, APAP was used as a model 
toxicant for Nrf2 activation in Nrf2 KO and WT mice. Mice were administered a single 400 
mg/kg APAP dose for 72 h. Dose and time-point selected were based on our single dose 
APAP study performed previously (Rudraiah et al., 2014), wherea 400 mg/kg APAP 
treatment increased Fmo3 protein levels at 72 h. Administration of 400 mg/kg APAP to 
male C57Bl/6J WT mice did not resultin significantlydifferent plasma ALT values at 72 h 
from vehicle controls. This is consistent with the previously reported results, indicating 
recovery from APAP-induced liver injury and increased Fmo3 protein expression in WT 
mice (Rudraiah et al., 2014). In contrast, plasma ALT activity is elevated at 72 h in Nrf2 KO 
mice receiving the same dose of APAP (176±12 IU/L) compared to vehicle control group 
(23±5 IU/L) (Figure 6A). This is again consistent with the literature and confirms that Nrf2 
plays animportant role not only in the magnitude of toxicity, but also the degree and rate of 
recovery from APAP-induced liver injury. Fmo3 mRNA levels were quantified by qRT-
PCR. The results in Figure 6B show that there is no change in Fmo3 mRNA levels at 72 h in 
wild-type mice administered 400 mg/kg APAP. This is again consistent with previous 
reports, where maximal Fmo3 mRNA expression is seen at 48 h after APAP administration 
and returns to normal by 72 h (Rudraiah et al., 2014). Notably, Fmo3 mRNA expression is 
significantly higherin Nrf2 KO mice 72 h after APAP treatment by 140±43-fold change 
compared to vehicle control group.
3.7 Fmo3 Protein Expression after APAP Treatment in Wild-Type and Nrf2 Knockout Mice
To examine the temporal changes in Fmo3 gene expression following APAP treatment in 
WT and Nrf2 KO mice, Fmo3 protein levels were quantified by western blotting and by 
measuring catalytic activity using MMI as substrate. Representative blots and associated 
densitometric analysis are shown in Figure 7A. Consistent with increased Fmo3 mRNA 
expression in Nrf2 KO mice administered APAP (400 mg/kg) at 72 h, Fmo3 protein levels 
are also significantly higher (5.1±1.3-fold) compared to vehicle control group. Measuring 
FMO catalytic activity using MMI can also quantitate Fmo3 protein induction(Zhang et al., 
2007). FMO specific activity increased significantly in Nrf2 KO livers (48±6±M/min/mg) at 
72 h after APAP compared to vehicle controls of either genotype (Figure 7B).
4. Discussion
FMO3 is a microsomal enzyme involved in the oxygenation of lipophilic substrates to more 
polar metabolites. Substrates include nitrogen-, sulfur- and phosphorous-containing drugs 
and xenobiotics, and most metabolic products of Fmo3 are considered to be non-
toxic(Krueger & Williams, 2005). Although FMOs were discovered in the 1960s (Miller et 
al., 1960) and further purified in 1972 (Ziegler & Mitchell, 1972), it was not until 2008 that 
Fmo3 induction by xenobiotics was demonstrated (Celius et al., 2008; Celius et al., 2010). In 
these studies, in spite ofa very large increase in Fmo3 mRNA level by AhR agonist 
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treatment, only a modest increase in protein level and function was reported. A gene array 
analysis performed in our laboratory also demonstrated Fmo3gene induction in the mouse 
model of APAP autoprotection(O'Connor et al., 2014). In this APAP autoprotection mouse 
model, we showed a significant increase in Fmo3 protein expression and function (Rudraiah 
et al., 2014). Constitutive Fmo3 expression in a female mouse liver is localized in the areas 
surrounding the periportal region (Janmohamed et al., 2004; Rudraiah et al., 2014). 
Following APAP exposure, the Fmo3 protein expression in APAP autoprotected livers was 
observed in the centrilobular regions where APAP-induced damage and/or hepatocellular 
compensatory proliferation is detected. Furthermore, we show that the enhanced expression 
of Fmo3 confers resistance against APAP-induced hepatotoxicity in mice (Rudraiah et al., 
2014).
In the present study, the effect of various other hepatotoxicants on Fmo3 gene expression in 
male C57BL/6J mouse liver was examined. A unifying theme for all hepatotoxicants used in 
our study is the oxidative stress. These models of oxidative stress used are very well studied 
with respect to activation of Nrf2-Keap1 regulatory pathway. This has been 
repeatedlydemonstrated in our laboratory and in the literature (Aleksunes et al., 2005; 
Aleksunes et al., 2006; Aleksunes et al., 2006; Bauer et al., 2000; Chiu et al., 2002; Goldring 
et al., 2004; Liu et al., 2013; Randle et al., 2008; Tanaka et al., 2009). Thus, we were 
confident that the treatments selected result in oxidative stress and therefore the need for 
measuring markers of oxidative stress for each experimentalgroup of hepatotoxicity was not 
deemed necessary.
Coincidentally, all of the hepatotoxicants selected produce cholestasis, with the exception of 
AlOH(Donepudi et al., 2012; Tanaka et al., 2009; Weerachayaphorn et al., 2012; Yamazaki 
et al., 2013). Furthermore, perturbation of bile acid homeostasis has been demonstrated to be 
an early event in the pathogenesis of drug induced liver injury(Yamazaki et al., 2013). To 
determine whether accumulation of bile acids is a signaling event regulating Fmo3, we 
measured total hepatic and plasma bile acid levels. Consistent with the literature, ANIT and 
BDL increased plasma and hepatic bile acid concentrations. A high CCl4dose did not 
significantly alter liver bile acid levels, but significantly increased plasma bile acid 
concentration. APAP tended to increase both hepatic and plasma bile acid concentrations, 
but this is not statistically significant.
In general, ANIT and BDL-mediated damage significantly increased liver Fmo3 mRNA 
expression. While CCl4-mediated liver injury significantly decreased Fmo3 mRNA 
expression, no change in expression is evidenced with AlOH. Fmo3 mRNA expressionin 
response to ANIT treatment precedes serum and hepatic bile acid accumulation and the 
maximal Fmo3 expression (both mRNA and protein) parallels the mild hepatocellular 
damage observed. This observation argues against the concept that hepatic bile acid 
accumulation is a pre-requisite for Fmo3 gene expression changes in the ANIT model. With 
BDL, unlike ANIT, Fmo3 mRNA induction is associated with higher serum and hepatic bile 
acid levels, but protein level does not change. Since tissues were analyzed 10 days after 
BDL, we do not have a sense of what the temporal relationship is between hepatic bile acid 
accumulation and elevated Fmo3 mRNA induction. This relationship deserves further 
attention based on the discussion of FXR signaling that can be found below.
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Overt ANIT-induced hepatocellular damage at 24 and 48 h decreased Fmo3 gene expression 
and the decease is statistically significant at 48 h compared to the 12 h ANIT-treated group. 
This observation with respect to the relationship between plasma ALT level and Fmo3 gene 
expression is consistent with our results with APAP hepatotoxicity. We have demonstrated 
in our APAP autoprotection mouse model that the APAP (400 mg/kg) pretreated group as 
well as the autoprotected group (APAP pretreatment: 400 mg/kg, APAP challenge: 600 
mg/kg) exhibit average plasma ALT values of about 250 IU/L and Fmo3 protein induction. 
The group that receives a toxic APAP dose of 600 mg/kg exhibits much greater average 
plasma ALT activity of about 1600 IU/L, but no Fmo3 gene induction (Rudraiah et al., 
2014).
One key feature that is consistent with APAP-, BDL- and ANIT-induced liver injury and 
enhanced Fmo3 gene expression is the magnitude in plasma ALT elevations. Mild ALT 
elevation is the common feature for all three models where Fmo3 mRNA induction is 
observed. Although BDL is a chronic injury model, it well known that the ALT values do 
not correlate well with the severity of liver damage particularly during fibrotic 
hepatocellular necrosis (Kallai et al., 1964). A similar clinical feature is also seen in cases of 
primary biliary cirrhosis (BDL models primary biliary cirrhosis in humans) (Hohenester et 
al., 2009). The lack of Fmo3 protein detection during BDL may be due to signal dilution by 
fibrotic liver tissue. It is also possible that under oxidative stress conditions some proteins 
involved in translation are oxidized in vivo inhibiting translation (Shenton et al., 2006). To 
add to this complexity, in spite of lower plasma ALT activity at 24 h (low dose CCl4), and 
48 h (both high and low dose CCl4) with CCl4, there is down-regulation of Fmo3 gene 
expression. In AlOH-treated livers, lower plasma ALT activity did not show any change in 
Fmo3 gene expression. This is suggestive of an unknown underlying mechanism unique to 
APAP, ANIT and BDL, which is contributing to Fmo3 mRNA induction. Studies are 
necessary to investigate the regional distribution of Fmo3 protein expression during ANIT- 
and BDL-induced liver injury to determine whether the protein expression in these models is 
localized to the portal vein, where ANIT- and BDL-induced hepatotoxicity is confined. 
Collectively, these data suggest that there is a threshold for degree of hepatic injury that 
results in increased Fmo3 gene and protein expression.More specifically,these data suggest 
that acute moderate or mild hepatotoxicity is optional for Fmo3 induction, while chronic, 
severe hepatotoxicity is not.
As discussed before, all models of hepatic injury used in the current study result in hepatic 
oxidative stress and activate the Nrf2-Keap1 regulatory pathway. Importantly, CRE analysis 
of differentially expressed genes in our APAP autoprotection study supportedan induction of 
the Nrf2 pathway (O'Connor et al., 2014). Additionally, Celius et al. (2008) showed that the 
5'-flanking region of the mouse Fmo3 contains multiple copies of the ARE (Celius et al., 
2008). Promoter analysis of mouse Fmo3 promoter (7 kb length)using MatInspector 
software (Genomatix, Munich, Germany), also showed an ARE at about 3 kb from the 
transcription start site (data not shown). We also found two other binding sites for Bach1, at 
600 bp and 2 kb from the Fmo3 transcription start site (data not shown). Bach1 is a 
regulatory mediator of Nrf2, in that it is a transcription repressor. Bach1 heterodimerizes 
with small Maf proteins in the absence of cellular stress and represses gene expression. In 
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the presence of oxidative stress, Bach1 is released from the Maf proteins and is replaced by 
Nrf2(Kaspar et al., 2009). Thus, using APAP as a model toxicant for Nrf2 activation, Fmo3 
gene expression was evaluated inNrf2 KO mice. Compared to APAP-treated wild-type mice, 
Nrf2 KO mice exhibit persistent and significant hepatocellular damage 72 h after APAP 
administration. Nrf2 KO mice are not only more susceptible to APAP-induced 
hepatocellular necrosis, but also fail to recover from injury as rapidly as the WT mice. This 
is consistent with the literature that describes Nrf2 as a master regulator of many 
cytoprotective genes involved in APAP-induced hepatotoxicity (Aleksunes et al., 2005; 
Aleksunes et al., 2006; Bauer et al., 2000; Chiu et al., 2002; Goldring et al., 2004). Finally, 
Fmo3 gene induction by APAP treatment in Nrf2 null mice suggests that the transcriptional 
regulation of Fmo3does not involve this transcription factor. The persistent mild 
hepatocellular injury and oxidative stress in Nrf2 KO mice most likely activates other 
signaling mechanisms involved in Fmo3 gene induction.
Future studies will investigate the role of other nuclear receptors in Fmo3 gene induction. 
Particularly, farnesoid X receptor (FXR) role in Fmo3 gene induction during APAP 
hepatotoxicity is worth investigating. FXR is one of the major bile acid sensors in the liver 
(Chiang, 2002) and plays a protective role during cholestasis development. Recently, it is 
shown that activation of FXR induces Fmo3 protein function (Bennett et al., 2013). 
Activation of FXR also provides protection against APAP-induced hepatotoxicity(F. Y. Lee 
et al., 2010). In addition, we discovered three binding sites for farnesoid X receptor-response 
element (FXRE) at about 1.6, 2.1 and 3.3 kb from the transcription start site on the mouse 
Fmo3 promoter (data not shown). Although, Pregnane X receptor (PXR) is also a bile acid 
sensor, no binding sites for PXR were found on promoter analysis and furthermore, PXR 
activation sensitizes APAP-induced hepatotoxicity (Cheng et al., 2009; Guo et al., 2004).
In conclusion, this study comprehensively characterizes for the first time temporal changes 
in Fmo3 gene expression during different conditions known to impart hepatic oxidative 
stress. In particular, we show that toxic ANIT and BDL significantly alter Fmo3 mRNA 
expression, but only Fmo3 protein with ANIT. The reason for this discrepancy is not yet 
clear or easy to rationalize. It is possible that Fmo3 is also protective during other chemical-
induced liver injury including ANIT. Even though the exact mechanism of Fmo3 gene 
expression or its role in protecting against toxicant-induced liver injury is not yet clear, the 
observed toxicity threshold for Fmo3 gene expression is intriguing. This work advances the 
lack of knowledge with regard to the inducibility of Fmo3 and its potential protective role in 
drug-induced liver injury.
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Fmo3 Flavin-containing monoxygenase-3
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ANIT Alpha-naphthylisothiocyanate
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CCl4 Carbon tetrachloride
AlOH Allyl alcohol
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
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Figure 1. Plasma ALT activity in mice treated with hepatotoxicants or BDL
Male C57BL/6J mice (n=6 per group) were treated with ANIT (50 mg/kg, po, 2,4,8,12,24 & 
48 h), CCl4 (10 & 30 μL/kg, ip, 24 & 48h), AlOH (30 & 60 mg/kg,ip, 6 & 24 h) or BDL (10 
d). Plasma was collected from mice at various time-points following hepatotoxicant 
treatment or the appropriate vehicle. The data are presented as mean plasma ALT (IU/L) ± 
SE. One-way ANOVA, t-test or two-way ANOVA was performed, appropriately, followed 
by the Dunnett's posttest for One-way ANOVA and the Bonferroni posttest for two-way 
ANOVA. Asterisks (*) represent a statistical difference (p < 0.05) between vehicle-treated 
and hepatotoxicant-treated group.
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Figure 2. Hepatic bile acid levels after hepatotoxicant administration or BDL
Livers were collected at the end of each study (24, 48 & 72h for APAP; 2,4,8,12,24 & 48h 
for ANIT; 10d for BDL; 24 & 48h for CCl4; and 6 & 24h for AlOH). Liver total bile acids 
were measured spectrophotometrically using a commercial bile acid assay kit. Hepatic total 
bile acids are expressed as mean hepatic bile acids (μmol/g) ± SE. One-way ANOVA, t-test 
or two-way ANOVA was performed, appropriately, followed by the Dunnett's posttest for 
one-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks (*) represent 
a statistical difference (p < 0.05) between vehicle-treated and hepatotoxicant-treated or BDL 
group.
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Figure 3. Blood levels of TotalBile acid in the mouse models of liver injury
Mice (n=6 per group) were administered APAP (400 mg/kg, ip, 24, 48 & 72h), ANIT (50 
mg/kg, po, 2,4,8,12,24 & 48h), CCl4(10 & 30 μL/kg, ip, 24 & 48 h), AlOH (30 & 60 mg/kg, 
ip, 6 & 24h) or BDL (10 d).Blood was collected and the plasma or serum (for BDL) was 
isolated by centrifugation. Total bile acid levels were measured spectrophotometrically 
using a commercial bile acid assay kit. Total bile acids are expressed as mean total bile acids 
(μmol/L) ± SE. Student's t-test,one-way ANOVA,or two-way ANOVA was performed, 
appropriately, followed by the Dunnett's posttest for one-way ANOVA and the Bonferroni 
posttest for two-way ANOVA. Asterisks (*) represent a statistical difference (p < 0.05) 
between vehicle-treated and hepatotoxicant-treated or BDL group.
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Figure 4. Quantitative RT-PCR analysis of liver Fmo3 transcripts after hepatotoxicant 
treatment or BDL
Livers were collected from mice (n=6) sacrificed at respective time-points (2,4,8,12,24 & 
48h for ANIT; 24 & 48h for CCl4; 6 & 24h for AlOH; and 10 d for BDL). RNA was 
isolated and cDNA was made using a commercial MMLV-RT kit. The cDNA samples were 
analyzed by quantitative RT-PCR using Fmo3 mouse-specific primers. Gene expression was 
normalized to the housekeeping gene β-actin. Fmo3 mRNA expression is presented as mean 
Fold Change ± SE. One-way ANOVA, t-test or two-way ANOVA was performed, 
appropriately, followed by the Dunnett's posttest for One-way ANOVA and the Bonferroni 
posttest for two-way ANOVA. Asterisks (*) represent a statistical difference (p < 0.05) 
between vehicle-treated and hepatotoxicant-treated or BDL group.
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Figure 5. Analysis of liver Fmo3 protein expression in the mouse models of liver injury by 
western blotting
Western immunoblots for Fmo3 were performed using liver microsomes from control and 
hepatotoxicant-treated or BDL mice. A custom-made rabbit anti-mouse Fmo3 primary 
antibody, described in Materials and Methods was used to detect Fmo3. Fmo3 protein levels 
were normalized to β-actin loading control. Microsomal proteins isolated from naïve female 
mouse liver were used as a positive control (indicated by “+” sign). The data are presented 
as blots and as mean Fmo3 protein expression (Fold Change) ± SE. One-way ANOVA, t-
test or two-way ANOVA was performed, appropriately, followed by the Dunnett's posttest 
for One-way ANOVA and the Bonferroni posttest for two-way ANOVA. Asterisks (*) 
represent a statistical difference (p < 0.05) between vehicle-treated and hepatotoxicant-
treated or BDL group.
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Figure 6. Plasma ALT activity and quantitative RT-PCR analysis of liver Fmo3 transcripts 
following a single dose APAP treatment in wild-type and Nrf2knockout mice
Plasma and livers were collected from mice 72 h following APAP (400 mg/kg) or vehicle 
treatment. (A) The data are presented as mean plasma ALT (IU/L) ± SE. (B) RNA was 
isolated from livers andcDNA samples were analyzed by quantitative RT-PCR using Fmo3 
mouse-specific primers. Gene expression was normalized to the housekeeping gene β-actin. 
Fmo3 mRNA expression are presented as mean Fold Change ± SE. Oneway ANOVA was 
performed followed by the Dunnett's post-test. Asterisks (*) represent a statistical difference 
(p < 0.05) between vehicle-treated group and APAP-treated group and hash (#) represent a 
statistical difference (p<0.05) compared with APAP-treated wild-type mice.
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Figure 7. Analysis of liver Fmo3 protein expression following a single dose APAP treatment in 
wild-type and Nrf2knockout mice by western blotting and enzyme activity assay
After overnight fasting, groups of wild-type and Nrf2 knockout mice received a single dose 
of 400 mg/kg APAP or vehicle. Livers were collected 72 h following APAP or vehicle 
treatments. Western blot for Fmo3 was performed using liver microsomes from control and 
APAP-treated mice. Equal protein loading (10 μg protein/lane) was confirmed by detection 
of β-actin. Microsomal proteins isolated from naïve female mouse liver were used as a 
positive control indicated by “+” sign. The data are presented as blots and as mean Fmo3 
protein expression (Fold Change) ± SE (A). FMO activity was measured in liver 
microsomes from control and APAP-treated mice using methimazole as substrate. Data are 
presented as mean Specific Activity (μM/min/mg) ± SE (B). Asterisks (*) represent a 
statistical difference (p < 0.05) between vehicle-treated group and APAP-treated group and 
hash (#) represent a statistical difference (p<0.05) compared with APAP-treated wild-type 
mice.
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